More specifically, NAT was delivered to 42 (44.2%) HER2+/HR+ patients, to 29 (69.1%) HER2+/HR-negative patients, to 63 (17.2%) HER2-negative/HR+ patients and to 26 (49.1%) triple negative breast cancer patients. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.